Summary
All extracted claims about Vitamin C interactions are not supported by the FDA-approved label; the provided claims do not align with on-label information.
Category Scores
Accurate Statements
Unsupported Statements
Vitamin C (ascorbic acid) has few major interactions with blood medications.
Not supported by FDA-approved label.
Effects vary by drug type.
Not supported by FDA-approved label.
High doses (over 1,000-2,000 mg daily) can alter absorption or blood levels for some.
Not supported by FDA-approved label.
Vitamin C does not significantly affect warfarin's anticoagulant action.
Not supported by FDA-approved label.
Studies show no consistent change in INR (clotting measure) from typical supplement doses.
Not supported by FDA-approved label.
Sudden high intake might slightly influence vitamin K metabolism indirectly, but evidence is weak.
Not supported by FDA-approved label.
No direct interactions reported between Vitamin C and antiplatelet medications (Aspirin, Clopidogrel, or Ticagrelor).
Not supported by FDA-approved label.
Vitamin C's mild antiplatelet effect at high doses (e.g., 2g+) could theoretically add to bleeding risk.
Not supported by FDA-approved label.
Clinical data shows no issues at standard antiplatelet doses (500-1,000 mg).
Not supported by FDA-approved label.
Vitamin C is safe with blood pressure medications (ACE inhibitors, beta blockers, calcium channel blockers).
Not supported by FDA-approved label.
Vitamin C may enhance benefits when used with blood pressure medications.
Not supported by FDA-approved label.
Trials found it improves endothelial function alongside drugs like enalapril or atenolol.
Not supported by FDA-approved label.
There are no adverse interactions reported with these blood pressure medications.
Not supported by FDA-approved label.
No known interactions between Vitamin C and statins.
Not supported by FDA-approved label.
Vitamin C can reduce statin-induced oxidative stress without affecting statin drug levels.
Not supported by FDA-approved label.
Daily multivitamins under 500 mg pose no risk.
Not supported by FDA-approved label.
Food sources pose no risk.
Not supported by FDA-approved label.
Supplements over 2,000 mg may cause stomach upset or kidney stone risk in prone individuals.
Not supported by FDA-approved label.
Supplements over 2,000 mg may indirectly affect blood meds.
Not supported by FDA-approved label.
High vitamin C might reduce efficacy of chemotherapy agents such as methotrexate.
Not supported by FDA-approved label.
Avoid high vitamin C if on methotrexate unless approved.
Not supported by FDA-approved label.
Vitamin C boosts iron absorption.
Not supported by FDA-approved label.
Vitamin C absorption boost could be risky for hemochromatosis.
Not supported by FDA-approved label.
Monitor kidney function if you have kidney issues, as vitamin C metabolizes there.
Not supported by FDA-approved label.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims are not supported by the label; potential risk cannot be inferred from label-based information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Multiple claims about Vitamin C interactions are not supported by FDA label.
Suggested Improvement
Limit statements to FDA-label information; avoid extrapolations; clearly indicate when statements are not on-label and cite sources.